Trials / Completed
CompletedNCT00366522
Study Evaluating LXR-623 in Healthy Subjects
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LXR-623 Administered Orally to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 19 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the safety and tolerability of a single dose of LXR-623 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LXR-623 |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2006-09-01
- Completion
- 2006-09-01
- First posted
- 2006-08-21
- Last updated
- 2009-08-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00366522. Inclusion in this directory is not an endorsement.